X
40.05
0.60 (1.52%)
| Penutupan Terdahulu | 39.45 |
| Buka | 39.02 |
| Jumlah Dagangan | 418,485 |
| Purata Dagangan (3B) | 369,459 |
| Modal Pasaran | 3,053,395,968 |
| Harga / Buku (P/B) | 3.72 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Feb 2025 - 3 Mar 2025 |
| EPS Cair (TTM) | -2.81 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.19% |
| Nisbah Semasa (MRQ) | 23.27 |
| Aliran Tunai Operasi (OCF TTM) | -153.55 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -104.09 M |
| Pulangan Atas Aset (ROA TTM) | -18.92% |
| Pulangan Atas Ekuiti (ROE TTM) | -26.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Xenon Pharmaceuticals Inc. | Menurun | Menurun |
AISkor Stockmoo
0.0
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.00 |
|
Xenon Pharmaceuticals Inc is a clinical-stage biopharmaceutical company committed to developing therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system, or CNS, conditions. The product candidates of the group include XEN1101, XEN901, and XEN496 for Epilepsy, and Nav1.7 oral inhibitors for Pain. Geographically the activities are carried out throughout Canada. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 0.38% |
| % Dimiliki oleh Institusi | 101.18% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 60.00 (Needham, 49.81%) | Beli |
| Median | 53.00 (32.34%) | |
| Rendah | 50.00 (Raymond James, 24.84%) | Beli |
| Purata | 54.33 (35.66%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 40.61 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Dec 2024 | 53.00 (32.33%) | Beli | 39.45 |
| 13 Nov 2024 | 53.00 (32.33%) | Beli | 41.97 | |
| Needham | 13 Nov 2024 | 60.00 (49.81%) | Beli | 41.97 |
| Raymond James | 10 Oct 2024 | 50.00 (24.84%) | Beli | 40.41 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| AULIN SHERRY | - | 39.35 | -25,334 | -996,893 |
| Jumlah Keseluruhan Kuantiti Bersih | -25,334 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -996,893 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 39.35 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| AULIN SHERRY | Pegawai | 18 Dec 2024 | Dibuang (-) | 6,625 | 39.35 | 260,694 |
| AULIN SHERRY | Pegawai | 18 Dec 2024 | Jual (-) | 18,709 | 39.35 | 736,199 |
| AULIN SHERRY | Pegawai | 18 Dec 2024 | Pelaksanaan pilihan | 25,334 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 06 Dec 2024 | Pengumuman | Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024 |
| 25 Nov 2024 | Pengumuman | Xenon to Showcase New Long-Term Azetukalner Data at AES 2024 |
| 13 Nov 2024 | Pengumuman | Xenon to Present at Upcoming Investor Conferences |
| 12 Nov 2024 | Pengumuman | Xenon Reports Q3 2024 Financial Results and Business Update |
| 05 Nov 2024 | Pengumuman | Xenon to Report Q3 2024 Financial Results on November 12, 2024 |
| 02 Oct 2024 | Pengumuman | Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |